Brain Injury - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Brain Injury - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Brain Injury - Pipeline Review, H2 2015', provides an overview of the Brain Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Brain Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Brain Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Brain Injury Overview 6
Therapeutics Development 7
Pipeline Products for Brain Injury - Overview 7
Pipeline Products for Brain Injury - Comparative Analysis 8
Brain Injury - Therapeutics under Development by Companies 9
Brain Injury - Therapeutics under Investigation by Universities/Institutes 10
Brain Injury - Pipeline Products Glance 11
Early Stage Products 11
Brain Injury - Products under Development by Companies 12
Brain Injury - Products under Investigation by Universities/Institutes 13
Brain Injury - Companies Involved in Therapeutics Development 14
Acorda Therapeutics, Inc. 14
Biogen, Inc. 15
Chiesi Farmaceutici SpA 16
Faron Pharmaceuticals Oy 17
FibroGen, Inc. 18
Virogenomics, Inc. 19
Brain Injury - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 27
Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
FG-4497 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
interferon beta-1a - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Peptide to Inhibit Pannexin-1 for Brain Injury - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PRE-084 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RTL-551 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Block TRPC3 for Acute Brain Injury - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Brain Injury - Recent Pipeline Updates 42
Brain Injury - Dormant Projects 44
Brain Injury - Discontinued Products 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for Brain Injury, H2 2015 7
Number of Products under Development for Brain Injury - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Products under Investigation by Universities/Institutes, H2 2015 13
Brain Injury - Pipeline by Acorda Therapeutics, Inc., H2 2015 14
Brain Injury - Pipeline by Biogen, Inc., H2 2015 15
Brain Injury - Pipeline by Chiesi Farmaceutici SpA, H2 2015 16
Brain Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2015 17
Brain Injury - Pipeline by FibroGen, Inc., H2 2015 18
Brain Injury - Pipeline by Virogenomics, Inc., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 26
Brain Injury Therapeutics - Recent Pipeline Updates, H2 2015 42
Brain Injury - Dormant Projects, H2 2015 44
Brain Injury - Discontinued Products, H2 2015 45